- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00679172
Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults
March 14, 2024 updated by: Emergent BioSolutions
A Randomised, Double-blind, Placebo-controlled, Single Dose, Dose Escalation Study to Determine the Immunogenicity, Safety and Tolerability of S. Typhi (Ty2 aroC-ssaV-) ZH9 at Doses of 5.0 x 10E9 CFU, 7.5 x 10E9 CFU, 1.1 x 10E10 and 1.7 x 10E10 CFU and 1.7 x 10E10 CFU, Following Oral Administration to Healthy, Typhoid Vaccine naïve Subjects in the USA.
This study is to investigate the safety, tolerability and immunogenicity of the typhoid fever vaccine candidate M01ZH09 manufactured at commercial scale, at a new manufacturing facility.
The vaccine will be delivered as a single oral dose to healthy, typhoid vaccine-naïve adults.
Study Overview
Status
Completed
Conditions
Detailed Description
This was a randomised, double-blind, placebo-controlled, single dose, dose escalation study with 4 dosing cohorts.
Within each cohort, 45 evaluable subjects were planned (36 subjects receiving M01ZH09, 9 receiving placebo).
Study Type
Interventional
Enrollment (Actual)
187
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
South Miami, Florida, United States, 33143
- Miami Research Associates
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- John Hopkins Bloomberg School of Public Health
-
-
Vermont
-
Burlington, Vermont, United States, 05405
- Unit of Infectious Diseases, University of Vermont College of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- healthy adult subjects aged 18 to 50 years inclusive, who are able and willing to give informed consent, following a detailed explanation of participation in protocol
- available for the duration of the study and available for scheduled and potential additional visits
Exclusion Criteria:
- women who are pregnant, breast-feeding or of childbearing potential and unwilling to use a reliable method of contraception throughout the study period
- history of anaphylactic shock following vaccination by any route have phenylketonuria
- hypersensitivity to any component of the vaccine or are hypersensitive to two of the following antibiotics: ciprofloxacin, azithromycin, ampicillin, trimethoprim sulfamethoxazole
- received antibiotic medication within 14 days prior to dosing
- received any vaccine within 4 weeks prior to dosing or plan to receive a vaccine within 4 weeks after dosing
- received any vaccine against Salmonella typhi (licensed or investigational) or ever suffered from typhoid fever
- subjects who test positive for hepatitis B, hepatitis C, HIV or human leucocyte antigen B-27
- known or suspected history of liver or active gall bladder disease, ongoing gastro-intestinal disease or abnormality
- commercial food handlers or health care workers with direct contact with high risk patients or who have household contacts with immuno-compromised individuals, pregnant women or children less than 2 years of age
- subjects who have a clinically significant amount of protein or haemoglobin in their urine or abnormality of their haematology or serum biochemistry parameters
- impairment of immune function or those receiving or have received cytotoxic drugs in the 6 months prior to study entry
- subjects who use antacids, proton pump inhibitors or H2 blockers on a regular basis or have consumed proton pump inhibitors or H2 blockers within 24 hours prior to dosing
- acute infections (including fever of 37.5 degrees Celsius or greater) on the day of dosing.
- subjects with chronic disease (e.g Crohn's disease, inflammatory bowel disease, diabetes) who cannot withstand a 3 hour fast
- substance abuse or a history of substance abuse that might interfere with participation in the study
- body mass index (BMI) is less than 19 or greater than 34 kg per m2
- clinically significant medical condition that precludes participation in the study
- subjects who have participated in an interventional clinical trial within 60 days of dosing
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: M01ZH09 Vaccine Candidate Cohort 1
Dose of 5.0 x 10^9 colony forming units (CFU) S. typhi (Ty2 aroC-ssaV-) ZH9 or placebo, administered as a single, oral dose
|
S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration
Excipients only, single dose, oral administration
|
Experimental: M01ZH09 Vaccine Candidate Cohort 2
Dose of 7.5 x 10^9 CFU S. typhi (Ty2 aroC-ssaV-) ZH9 or placebo, administered as a single, oral dose
|
Excipients only, single dose, oral administration
S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration
|
Experimental: M01ZH09 Vaccine Candidate Cohort 3
Dose of 1.1 x 10^10 CFU S. typhi (Ty2 aroC-ssaV-) ZH9 or placebo, administered as a single, oral dose
|
Excipients only, single dose, oral administration
S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration
|
Experimental: M01ZH09 Vaccine Candidate Cohort 4
Dose of of 1.7 x 10^10 CFU S. typhi (Ty2 aroC-ssaV-) ZH9 or placebo, administered as a single, oral dose
|
Excipients only, single dose, oral administration
S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number and Proportion of Subjects Reporting Suspected Unexpected Serious Adverse Reactions.
Time Frame: From start of dosing to 28 days post-dosing.
|
Number and proportion of subjects reporting suspected unexpected serious adverse reactions (SUSARs).
|
From start of dosing to 28 days post-dosing.
|
Number and Proportion of Subjects Experiencing Symptomatic Fever.
Time Frame: From start of dosing to 14 days post-dosing.
|
Number and proportion of subjects experiencing symptomatic (e.g., chills, rigors, sweating, headache, myalgia etc.) elevated body temperature of 38.0°C or more in the 14 days following dosing.
|
From start of dosing to 14 days post-dosing.
|
Number of Subjects Having Clinically Significant Changes in Laboratory Test Parameters.
Time Frame: From start of dosing to 28 days post-dosing.
|
Number of subjects having clinically significant changes in clinical laboratory test parameters.
|
From start of dosing to 28 days post-dosing.
|
Number of Subjects Reporting Treatment-related TEAEs.
Time Frame: From start of dosing to 28 days post-dosing.
|
Number of subjects having TEAEs considered by the principal investigator to be "possibly" or "probably" related to treatment.
|
From start of dosing to 28 days post-dosing.
|
Number and Proportion of Subjects Experiencing Bacteraemia.
Time Frame: From start of dosing to 28 days post-dosing.
|
Number and proportion of subjects experiencing a proven bacteraemia attributed to the vaccine strain S. typhi (Ty2 aroC-ssaV-) ZH9.
|
From start of dosing to 28 days post-dosing.
|
Number of Subjects Having Shedding in Stool of Salmonella Typhi (S. Typhi) (Ty2 aroC-ssaV-) ZH9.
Time Frame: Beyond 7 days post-dosing through 14 days post-dosing (Cohorts 1-3) or through 21 days post-dosing (Cohort 4).
|
Number of subjects having shedding in stool of S. typhi (Ty2 aroC-ssaV-) ZH9.
Subjects were evaluated beyond Day 14 only in Cohort 4.
|
Beyond 7 days post-dosing through 14 days post-dosing (Cohorts 1-3) or through 21 days post-dosing (Cohort 4).
|
Number and Proportion of Subjects Developing an Immune Response as Determined by the Level of IgG and/or IgA Antibodies for S. Typhi Lipopolysaccharide (LPS).
Time Frame: From baseline (pre-dose) to Days 14 or 28 (IgG) or to Days 7 or 14 (IgA).
|
Number and proportion of subjects with increase of 70% (fold change of 1.7) in S. typhi LPS-specific serum IgG at Days 14 or 28 AND/OR increase of 50% (fold change of 1.5) in S. typhi LPS-specific serum IgA at Days 7 or 14.
Serum IgG and IgA were assayed using enzyme-linked immunosorbent assay (ELISA).
|
From baseline (pre-dose) to Days 14 or 28 (IgG) or to Days 7 or 14 (IgA).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number and Proportion of Subjects Developing an Immune Response as Determined by the Level of IgA Antibodies for S. Typhi LPS.
Time Frame: From baseline (pre-dose) to Days 7 or 14.
|
Number and proportion of subjects with increase of 50% (fold change of 1.5) in S. typhi LPS-specific serum IgA at Days 7 or 14.
Serum IgA was assayed using ELISA.
|
From baseline (pre-dose) to Days 7 or 14.
|
Number and Proportion of Subjects Developing an Immune Response as Determined by the Level of IgG Antibodies for S. Typhi LPS.
Time Frame: From baseline (pre-dose) to Days 14 or 28.
|
Number and proportion of subjects with increase of 70% (fold change of 1.7) in S. typhi LPS-specific serum IgG at Days 14 or 28.
Serum IgG was assayed using ELISA.
|
From baseline (pre-dose) to Days 14 or 28.
|
Number and Proportion of Subjects Developing an Immune Response as Determined by the Level of IgG Antibodies for S. Typhi LPS.
Time Frame: From baseline (pre-dose) to Days 7, 14, or 28.
|
Number and proportion of subjects with an increase of 70% (fold change of 1.7) in S. typhi LPS-specific serum IgG at Days 7, 14 or 28.
Serum IgG was assayed using ELISA.
|
From baseline (pre-dose) to Days 7, 14, or 28.
|
Number and Proportion of Subjects Developing an Immune Response at the Target Dose of 7.5 x 10^9 CFU (Cohort 2) as Determined by the Number of Antibody Secreting Cells (ASCs) Secreting IgA and/or Fold Change in IgG.
Time Frame: At Day 7 (IgA); and from baseline (pre-dose) to Day 28 (IgG).
|
Number and proportion of subjects with ≥ 4 ASCs per 10^6 peripheral blood mononuclear cells (PBMCs) at Day 7 secreting IgA specific for S. typhi LPS (detected by enzyme-linked immunospot assay [ELISPOT]) AND/OR 4-fold increase for serum IgG on Day 28 compared to baseline (assay using endpoint titre ELISA).
|
At Day 7 (IgA); and from baseline (pre-dose) to Day 28 (IgG).
|
Number and Proportion of Subjects Developing an Immune Response at the Target Dose of 7.5 x 10^9 CFU (Cohort 2) as Determined by the Number of ASCs Secreting IgA.
Time Frame: Day 7.
|
Number and proportion of subjects with ≥ 4 ASCs per 10^6 PBMCs at Day 7 secreting IgA specific for S. typhi LPS (detected by ELISPOT).
|
Day 7.
|
Number and Proportion of Subjects Developing an Immune Response at the Target Dose of 7.5 x 10^9 CFU (Cohort 2) as Determined by the Fold Change in IgG.
Time Frame: From baseline (pre-dose) to Day 28.
|
Number and proportion of subjects with 4-fold increase for serum IgG on Day 28 compared to baseline (assay using endpoint titre ELISA).
|
From baseline (pre-dose) to Day 28.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Stephen Lockhart, DM, Emergent BioSolutions
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2008
Primary Completion (Actual)
December 1, 2008
Study Completion (Actual)
December 1, 2008
Study Registration Dates
First Submitted
May 14, 2008
First Submitted That Met QC Criteria
May 15, 2008
First Posted (Estimated)
May 16, 2008
Study Record Updates
Last Update Posted (Actual)
April 9, 2024
Last Update Submitted That Met QC Criteria
March 14, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MS01.13
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Typhoid
-
University of Maryland, BaltimoreActive, not recruitingTyphoid VaccinationUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
University of OxfordCompletedTyphoid Vaccine on Sleep
-
University of Maryland, BaltimoreRecruitingTyphoid and/or Cholera VaccinationUnited States
-
International Centre for Diarrhoeal Disease Research...Recruiting
-
International Vaccine InstituteUniversity of Cambridge; Institute of Tropical Medicine, Belgium; Institut National...RecruitingTyphoid FeverCongo, The Democratic Republic of the
-
International Vaccine InstituteBill and Melinda Gates Foundation; SK Bioscience Co., Ltd.Completed
-
International Vaccine InstituteBill and Melinda Gates Foundation; SK Bioscience Co., Ltd.Completed
-
Helsinki University Central HospitalUnknown
-
International Vaccine InstituteGlaxoSmithKline; Wellcome Trust; Aga Khan University; University of Western Ontario...CompletedTyphoid | Paratyphoid FeverPakistan
Clinical Trials on Dose of 5.0 x 10^9 CFU (Cohort 1)
-
Merck Sharp & Dohme LLCTerminated
-
University of OxfordCompleted
-
PATHCompleted
-
National Institute of Allergy and Infectious Diseases...Rho Federal Systems Division, Inc.; Autoimmunity Centers of ExcellenceTerminatedPemphigus Vulgaris | Pemphigus FoliaceusUnited States
-
Crucell Holland BVThe PATH Malaria Vaccine Initiative (MVI); Seattle Children's Research Institute...Completed
-
S.Biomedics Co., Ltd.Dt&SanomedicsActive, not recruitingCritical Limb IschemiaKorea, Republic of
-
GlaxoSmithKlineCompletedHepatitis CUnited States
-
Milton S. Hershey Medical CenterWithdrawnPneumonia | Acute Respiratory Distress Syndrome | Respiratory Virus Infection
-
Auro Vaccines LLCUnited States Department of Defense; AccelovanceCompletedEbola Virus DiseaseUnited States
-
Medical College of WisconsinNot yet recruiting